.svg){kind=small}
May-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
Canna Clinicals concentrated 84.75% of May 2026 sales in Tincture & Sublingual, where category sales grew 6.10% year over year but slipped 0.44% month over month, while Capsules fell to 7.68% share with a 37.47% YoY decline and a 29.29% MoM drop. Topical accounted for 7.57% share with a 24.08% MoM decline and no YoY baseline, and the brand’s average price fell 24.13% YoY to $39.76 even as total brand sales rose 8.50% YoY; in New York Tincture & Sublingual rank stood at 8. The pattern implies a reliance on one category to offset sharp contraction in Capsules and Topical, with price compression aiding unit velocity but concentrating risk in a single segment and market rank band.
With Tincture & Sublingual at 84.75% share and ranked 8th in New York, the 0.44% MoM dip alongside a 6.10% YoY gain suggests incremental share defense rather than expansion, while double‑digit MoM declines in Capsules (29.29%) and Topical (24.08%) narrow diversification levers. The 24.13% YoY price decrease paired with 8.50% YoY sales growth and a 39.38% 24‑month increase indicates unit-led gains that could be vulnerable if Tincture & Sublingual momentum stalls; strategically, the brand’s positioning leans toward value-access in its core form factor, implying the need to stabilize secondary categories to reduce exposure to single-category rank volatility.
Competitive Landscape
Canna Clinicals ranks #8 in New York Tincture & Sublingual for May 2026, improving 1 position from #9 year over year, but slipping 2 spots from #6 in February 2026 and sitting 3 positions below its peak of #5 in May 2024; meanwhile, Ayrloom held #1 year over year and remains #1 as of May 2026 while growing sales 22.54%, and Veterans Choice Creations (VCC) rose from #4 to #3 with 14.01% sales growth as Mfny (Marijuana Farms New York) slid from #3 to #4 alongside a -34.58% sales change; against that mix of upward and downward moves, the modest YoY rank gain paired with a 2-place decline versus three months ago implies Canna Clinicals is stabilizing mid-pack rather than setting up for a near-term return to its May 2024 peak.
Notable Products
CBD/CBN/THC Sleep Tincture (300mg CBD, 300mg CBN, 150mg THC) posted the largest month-over-month gain at 69.3% and climbed to rank 3, while the CBD/THC 1:10 Max Strength Tincture (100mg CBD, 1000mg THC, 30ml) fell 11.2% but still held rank 1. Two capsule SKUs dropped sharply with the CBD/THC 1:1 Max Strength Capsules 10-Pack (100mg CBD, 100mg THC) down 33.9% at rank 5 and the CBD/THC/CBG1:1:1 Relief Complex Capsules 20-Pack (100mg CBD, 100mg THC, 100mg CBG) down 35.3% at rank 8. With three of the top four in Tincture & Sublingual, the mix tilts toward higher-THC and sleep-focused tinctures despite capsule volatility, implying a pivot toward fast-acting sublingual solutions over oral formats.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
